current research into jak inhibitors - specifially ruxolitinib, pacritinib, and momelotinib
Published 8 years ago • 810 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
3:35
considering the key benefits of each jak inhibitor approved for the treatment of mpns
-
3:21
looking beyond jak inhibitors: novel targeted therapies and strategies for mpn treatment
-
4:25
update on momelotinib for myelofibrosis
-
1:38
considerations when selecting between jak inhibitors for patients with mpns
-
1:24
understanding aberrant signaling pathways to prevent resistance to jak2 inhibitors in mpns
-
0:40
what is comprehensive genomic profiling? - how it helps cancer treatment
-
1:09
emerging treatment options for refractory immune thrombocytopenia
-
1:53
phase i trial evaluating a gamma secretase inhibitor in combination with car-t cells in r/r myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
1:10
the sensitization of immune checkpoint inhibitors with subsequent chemotherapy in r/r hl
-
2:02
research projects within the en-acti2ng program
-
3:02
limitations of current risk stratification systems in fl & treatment options for high-risk patients
-
4:01
adverse events seen with jak inhibition in mpn
-
1:06
insights into toll-like receptor signaling and implications for car-t therapy
-
6:20
jak inhibitor treatment shows benefit for patients with interferonopathies
-
39:50
sensitizing p-selectin-expressing brain malignancies to immune checkpoint modulators
-
1:48
the post-car prognostic index (pc-pi) for predicting os in large b-cell lymphoma
-
2:42
steroid-refractory gvhd: treatment with jak inhibitors
-
1:19
the emerging role of checkpoint inhibitors in liver cancer